CONRAD Congratulates the CDC Bangkok Tenofovir Study Team

June 13, 2013

The Centers for Disease Control and Prevention (CDC) announced results of a study using oral tenofovir in 2,400 intravenous drug users in Thailand. Also known as pre-exposure prophylaxis (PrEP), the oral tenofovir tablets reduced HIV infections by an average of 49%. As in other successful prevention studies, it was shown that the more adherent the participants were to the drug regimen, the higher the rate of protection. Those who used oral tenofovir most consistently were 74% less likely to become infected. The Bangkok Tenofovir Study is the first to prove that PrEP is effective in reducing HIV infections in intravenous drug users. According to The New York Times, 10% of new HIV infections globally are due to needle sharing.

CONRAD congratulates the CDC and the Thai Ministry of Health for a well run study and excellent results. We hope that these results are inspiring to those participants currently in prevention trials, and that they are encouraged to use their products as directed.  

1911 North Fort Myer Drive, Suite 900, Arlington, Virginia 22209   T: (703) 524-4744 |